Key Highlights

  • Shares are trading at $11.25 in pre-market activity, down 3.52% from Wednesday's close of $11.66.
  • The decline extends last week's steep selloff after a law firm disclosed a securities-fraud investigation into the company's disclosure practices.
  • The Phase 3 REGAL trial has reached its pre-specified 80th-event survival trigger for GPS in acute myeloid leukemia.
  • The company maintains a cash position of approximately $138 million against minimal liabilities.

Selloff Extends on a Securities-Fraud Investigation

SELLAS Life Sciences (NASDAQ:SLS) shares fell further in pre-market trading Thursday, extending last week's steep selloff after a law firm disclosed a securities-fraud investigation into the company for allegedly failing to promptly disclose that its Phase 3 REGAL trial had reached the pre-specified 80th-event survival trigger for its lead candidate, galinpepimut-S, in acute myeloid leukemia. SELLAS Life Sciences is a late-stage clinical biopharmaceutical company headquartered in New York, New York, developing novel immunotherapeutics for a broad range of cancer indications, including hematologic malignancies and solid tumors.

The disclosure had already sent shares down more than 14% on September 14, and the stock has continued to slide as investigation developments filter through this week.

Valuation Commentary Compounds the Pressure

Fresh valuation commentary from an independent research site this week flagged SELLAS as significantly Overvalued on a price-to-book basis, citing a multiple near 17.1 times versus a typical biotech peer average of roughly two to three times, a gap that comes as the company reported a quarterly net loss of approximately $32 million.

Balance Sheet Strength Offers a Partial Offset

Even amid the investigation concerns, SELLAS maintains a cash position of approximately $138 million against minimal liabilities, a Balance Sheet cushion that investors are weighing against questions about the credibility of management's prior trial-timeline disclosures.

Outlook: Topline Data Delay Keeps Investors on Edge

SELLAS shares remain under pressure as investors await further clarity on the delayed REGAL trial topline data and any additional developments in the disclosure investigation. Resolution of both issues will likely determine whether the stock can stabilize from its recent slide.